Julie Feder

No open positions remaining

56 year

Health Technology

Commercial Services

Consumer Services

Profile

Julie B. Feder is currently Chief Financial Officer at Obsidian Therapeutics, Inc. Formerly, Ms. Feder was Chief Financial Officer at Aura Biosciences, Inc. from 2018 to 2024, Chief Financial Officer at Verastem, Inc. from 2017 to 2018, Chief Financial Officer at Clinton Health Access Initiative from 2011 to 2017, Vice President-Internal Audit at Genzyme Corp.
from 2008 to 2011, and Senior Manager-Audit, Consulting & Enterprise Risk at Deloitte & Touche LLP from 1991 to 2008.
Ms. Feder completed undergraduate studies at Sy Syms School of Business.

Julie Feder active positions

Companies	Position	Start

All active positions of Julie Feder

Former positions of Julie Feder

Companies	Position	End
AURA BIOSCIENCES, INC.	Director of Finance/CFO	25/10/2024
VERASTEM, INC.	Director of Finance/CFO	01/06/2018
Clinton Health Access Initiative Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment	Director of Finance/CFO	01/07/2017
Deloitte & Touche LLP Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services	Corporate Officer/Principal	01/01/2008
Genzyme Corp. Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology	Comptroller/Controller/Auditor	-

See the detail of Julie Feder's experience

Training of Julie Feder

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Julie Feder's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
Genzyme Corp. Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology	Health Technology
Aura Biosciences, Inc. Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications	Health Technology
Deloitte & Touche LLP Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services	Commercial Services
Verastem, Inc. Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs	Health Technology
Clinton Health Access Initiative Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment	Commercial Services
Sy Syms School of Business Sy Syms School of Business Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services